- Home
- ITGR vs GH Comparison
ITGR vs GH Comparison
Compare ITGR & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITGR
- GH
- Stock Information
- Founded
- ITGR 1970
- GH 2011
- Country
- ITGR United States
- GH United States
- Employees
- ITGR N/A
- GH N/A
- Industry
- ITGR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- GH Medical Specialities
- Sector
- ITGR Health Care
- GH Health Care
- Exchange
- ITGR Nasdaq
- GH Nasdaq
- Market Cap
- ITGR 4.2B
- GH 4.9B
- IPO Year
- ITGR 2000
- GH 2018
- Fundamental
- Price
- ITGR $122.57
- GH $50.09
- Analyst Decision
- ITGR Strong Buy
- GH Strong Buy
- Analyst Count
- ITGR 10
- GH 20
- Target Price
- ITGR $145.90
- GH $53.85
- AVG Volume (30 Days)
- ITGR 383.7K
- GH 2.0M
- Earning Date
- ITGR 07-24-2025
- GH 04-30-2025
- Dividend Yield
- ITGR N/A
- GH N/A
- EPS Growth
- ITGR N/A
- GH N/A
- EPS
- ITGR 2.18
- GH N/A
- Revenue
- ITGR $1,746,192,000.00
- GH $773,996,000.00
- Revenue This Year
- ITGR $11.03
- GH $23.16
- Revenue Next Year
- ITGR $7.29
- GH $21.40
- P/E Ratio
- ITGR $55.45
- GH N/A
- Revenue Growth
- ITGR 10.19
- GH 28.20
- 52 Week Low
- ITGR $104.93
- GH $20.14
- 52 Week High
- ITGR $146.36
- GH $52.92
- Technical
- Relative Strength Index (RSI)
- ITGR 58.08
- GH 70.03
- Support Level
- ITGR $120.00
- GH $47.16
- Resistance Level
- ITGR $123.01
- GH $50.54
- Average True Range (ATR)
- ITGR 2.27
- GH 2.42
- MACD
- ITGR 0.34
- GH 1.32
- Stochastic Oscillator
- ITGR 98.22
- GH 96.83
About ITGR Integer Holdings Corporation
Integer Holdings Corp is a manufacturer of medical device components used by original equipment manufacturers in the medical industry. The company also develops batteries used in nonmedical applications in the energy, military, and environmental markets. The firm organizes itself into one segment and derives its revenues from three product lines: Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation and Other Markets. The company earns more than half of its revenue in the United States.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.